tetano
Editor, Senior Moderator
Mayo Clin Proc
. 2022 Sep;97(9):1641-1648.
doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23.
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
Raymund R Razonable[SUP] 1 [/SUP], John C O'Horo[SUP] 2 [/SUP], Douglas W Challener[SUP] 2 [/SUP], Lori Arndt[SUP] 2 [/SUP], Richard F Arndt[SUP] 2 [/SUP], Caroline G Clune[SUP] 2 [/SUP], Tracy L Culbertson[SUP] 2 [/SUP], Scott T Hall[SUP] 2 [/SUP], Alexander Heyliger[SUP] 2 [/SUP], Tammy A Jackson[SUP] 2 [/SUP], Brian D Kennedy[SUP] 2 [/SUP], Jennifer Larsen[SUP] 2 [/SUP], Sara N Hanson[SUP] 2 [/SUP], Perry W Sweeten[SUP] 2 [/SUP], Sidna M Tulledge-Scheitel[SUP] 2 [/SUP], Ravindra Ganesh[SUP] 2 [/SUP]
Affiliations
Abstract
Objective: To describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab treatment of mild to moderate coronavirus disease 2019 (COVID-19) during the severe acute respiratory coronavirus 2 (SARS-CoV-2) B.1.617.2 Delta surge.
Methods: This is a retrospective study of high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 between August 1, 2021, and December 1, 2021. Rates of severe disease, hospitalization, intensive care unit admission, and death were assessed.
Results: Among 10,775 high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab for mild to moderate COVID-19 during the Delta surge, 287 patients (2.7%) developed severe disease that led to hospitalization, oxygen supplementation, or death within 30 days after treatment. The rates of severe disease were low among patients treated with bamlanivimab-etesevimab (1.2%), casirivimab-imdevimab (2.9%), and sotrovimab (1.6%; P<.01). The higher rate of severe outcomes among patients treated with casirivimab-imdevimab may be related to a significantly lower COVID-19 vaccination rate in that cohort. Intensive care unit admission was comparable among patients treated bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab (1.0%, 1.0%, and 0.4%, respectively).
Conclusion: This real-world study of a large cohort of high-risk patients shows low rates of severe disease, hospitalization, intensive care unit admission, and mortality after treatment with bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 during the SARS-CoV-2 Delta surge.
. 2022 Sep;97(9):1641-1648.
doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23.
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
Raymund R Razonable[SUP] 1 [/SUP], John C O'Horo[SUP] 2 [/SUP], Douglas W Challener[SUP] 2 [/SUP], Lori Arndt[SUP] 2 [/SUP], Richard F Arndt[SUP] 2 [/SUP], Caroline G Clune[SUP] 2 [/SUP], Tracy L Culbertson[SUP] 2 [/SUP], Scott T Hall[SUP] 2 [/SUP], Alexander Heyliger[SUP] 2 [/SUP], Tammy A Jackson[SUP] 2 [/SUP], Brian D Kennedy[SUP] 2 [/SUP], Jennifer Larsen[SUP] 2 [/SUP], Sara N Hanson[SUP] 2 [/SUP], Perry W Sweeten[SUP] 2 [/SUP], Sidna M Tulledge-Scheitel[SUP] 2 [/SUP], Ravindra Ganesh[SUP] 2 [/SUP]
Affiliations
- PMID: 36058578
- DOI: 10.1016/j.mayocp.2022.06.015
Abstract
Objective: To describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab treatment of mild to moderate coronavirus disease 2019 (COVID-19) during the severe acute respiratory coronavirus 2 (SARS-CoV-2) B.1.617.2 Delta surge.
Methods: This is a retrospective study of high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 between August 1, 2021, and December 1, 2021. Rates of severe disease, hospitalization, intensive care unit admission, and death were assessed.
Results: Among 10,775 high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab for mild to moderate COVID-19 during the Delta surge, 287 patients (2.7%) developed severe disease that led to hospitalization, oxygen supplementation, or death within 30 days after treatment. The rates of severe disease were low among patients treated with bamlanivimab-etesevimab (1.2%), casirivimab-imdevimab (2.9%), and sotrovimab (1.6%; P<.01). The higher rate of severe outcomes among patients treated with casirivimab-imdevimab may be related to a significantly lower COVID-19 vaccination rate in that cohort. Intensive care unit admission was comparable among patients treated bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab (1.0%, 1.0%, and 0.4%, respectively).
Conclusion: This real-world study of a large cohort of high-risk patients shows low rates of severe disease, hospitalization, intensive care unit admission, and mortality after treatment with bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 during the SARS-CoV-2 Delta surge.